Lineage Cell Therapeutics (NYSEAMERICAN:LCTX) Given “Buy” Rating at HC Wainwright

Lineage Cell Therapeutics (NYSEAMERICAN:LCTX)‘s stock had its “buy” rating restated by equities research analysts at HC Wainwright in a note issued to investors on Friday,Benzinga reports. They currently have a $9.00 target price on the stock.

Several other analysts have also recently issued reports on LCTX. Maxim Group lowered their target price on shares of Lineage Cell Therapeutics from $5.00 to $3.00 and set a “buy” rating on the stock in a research note on Friday, January 10th. D. Boral Capital reaffirmed a “buy” rating and set a $2.00 price objective on shares of Lineage Cell Therapeutics in a report on Friday, January 3rd. Five equities research analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock presently has a consensus rating of “Buy” and a consensus target price of $4.80.

Lineage Cell Therapeutics Price Performance

LCTX opened at $0.63 on Friday. The stock has a market capitalization of $138.86 million, a PE ratio of -5.25 and a beta of 1.18. Lineage Cell Therapeutics has a twelve month low of $0.48 and a twelve month high of $1.61.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the stock. Defender Capital LLC. boosted its stake in Lineage Cell Therapeutics by 19.2% during the 4th quarter. Defender Capital LLC. now owns 5,963,348 shares of the company’s stock valued at $2,997,000 after purchasing an additional 961,150 shares during the last quarter. SG Americas Securities LLC increased its holdings in Lineage Cell Therapeutics by 35.5% in the 4th quarter. SG Americas Securities LLC now owns 68,973 shares of the company’s stock worth $35,000 after buying an additional 18,053 shares in the last quarter. JPMorgan Chase & Co. increased its holdings in Lineage Cell Therapeutics by 13.9% in the 3rd quarter. JPMorgan Chase & Co. now owns 677,162 shares of the company’s stock worth $613,000 after buying an additional 82,864 shares in the last quarter. Barclays PLC raised its position in Lineage Cell Therapeutics by 311.3% in the 3rd quarter. Barclays PLC now owns 211,300 shares of the company’s stock worth $192,000 after buying an additional 159,924 shares during the last quarter. Finally, Geode Capital Management LLC lifted its stake in Lineage Cell Therapeutics by 2.3% during the 3rd quarter. Geode Capital Management LLC now owns 3,679,280 shares of the company’s stock valued at $3,331,000 after acquiring an additional 83,274 shares during the period. Hedge funds and other institutional investors own 62.47% of the company’s stock.

Lineage Cell Therapeutics Company Profile

Lineage Cell Therapeutics, Inc, a clinical-stage biotechnology company, develops novel cell therapies for unmet medical needs in the United States and internationally. The company develops OpRegen, an allogeneic retinal pigment epithelium cell replacement therapy, which is in Phase 2a clinical trial for the treatment of the dry age-related macular degeneration; OPC1, an allogeneic oligodendrocyte progenitor cell therapy that is in Phase 1/2a multicenter clinical trial for the treatment of cervical spinal cord injuries; and VAC, an allogeneic cancer immunotherapy of antigen-presenting dendritic cells, which is in Phase I clinical trial to treat non-small cell lung cancer.